Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 24;10(5):e27047.
doi: 10.1016/j.heliyon.2024.e27047. eCollection 2024 Mar 15.

The effects of transcription factor 7-like 2 rs7903146 and paired box 4 rs2233580 variants associated with type 2 diabetes on the therapeutic efficacy of hypoglycemic agents

Nipaporn Teerawattanapong  1   2 , Lanraphat Srisawat  1   2 , Tassanee Narkdontri  1   2 , Pa-Thai Yenchitsomanus  2   3 , Watip Tangjittipokin  1   2 , Nattachet Plengvidhya  2   4
Affiliations

The effects of transcription factor 7-like 2 rs7903146 and paired box 4 rs2233580 variants associated with type 2 diabetes on the therapeutic efficacy of hypoglycemic agents

Nipaporn Teerawattanapong et al. Heliyon. .

Abstract

Aim: This study aims to investigate the effects of the TCF7L2 rs7903146 and PAX4 rs2233580 (R192H) variants associated with T2D on the therapeutic efficacies of various HAs in patients with T2D after follow-up for 3 years.

Methods: A total of 526 patients who were followed up at the Diabetic Clinic of Siriraj Hospital during 2016-2019 were enrolled. The variants TCF7L2 rs7903146 and PAX4 rs2233580 (R192H) were genotyped using the RNase H2 enzyme-based amplification (rhAmp) technique and the associations between genotypes and glycemic control after treatments with different combinations HA were evaluated using Generalized Estimating Equations (GEE) analysis.

Results: Patients who carried TCF7L2 rs7903146C/T + T/T genotypes when they were treated with biguanide alone had significantly lower fasting plasma glucose (FPG) than those of the patients who carried the C/C genotype (p = 0.01). Patients who carried the PAX4 rs2233580 G/G genotype when they were treated with sulfonylurea alone had significantly lower FPG than those of the patients who carried G/A + A/A genotypes (p = 0.04).

Conclusion: Genotypes of TCF7L2 rs7903146 and PAX4 rs2233580 (R192H) variants associated with T2D influence the therapeutic responses to biguanide and sulfonylurea. Different genotypes of these two variants might distinctively affect the therapeutic effects of HAs. This finding provides evidence of pharmacogenetics in the treatment of diabetes.

Keywords: PAX4; Paired box gene 4; Pharmacogenetics; TCF7L2; Transcription factor 7-like 2; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Fasting plasma glucose (FPG) changes in comparison to TCF7L2 rs7903146 and PAX4 rs2233580 (R192H) genotypes following three years of hypoglycemic medications therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., et al. 9 edition. Diabetes research and clinical practice; 2019. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas; p. 157. - PubMed
    1. International Diabetes Federation . IDF Diabetes Atlas; 2019. Global Picture; pp. 32–61.
    1. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. - PubMed
    1. American Diabetes Association Approaches to glycemic treatment. Diabetes Care. 2014;38:S41–S48. - PubMed
    1. Daniels M.A., Kan C., Willmes D.M., Ismail K., Pistrosch F., Hopkins D., et al. Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J. 2016;16:399–410. - PubMed

LinkOut - more resources